Sofosbuvir and risk of estimated glomerular filtration rate decline or end‐stage renal disease in patients with renal impairment

BACKGROUND: Sofosbuvir, a prodrug nucleoside inhibitor of hepatitis C virus, has a predominant circulating metabolite that is renally eliminated. Whether sofosbuvir is associated with chronic kidney disease (CKD) progression is not well understood. METHODS: We performed a retrospective analysis of p...

Descripción completa

Detalles Bibliográficos
Autores principales: Sulkowski, Mark, Telep, Laura E., Colombo, Massimo, Durand, Francois, Reddy, K. Rajender, Lawitz, Eric, Bourlière, Marc, Cheinquer, Nelson, Scherbakovsky, Stacey, Ni, Liyun, Force, Lindsey, Ramroth, Heribert, Gaggar, Anuj, Chokkalingam, Anand P., Sise, Meghan E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Sofosbuvir and Risk of Gfr Decline
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313579/
https://www.ncbi.nlm.nih.gov/pubmed/35235245
http://dx.doi.org/10.1111/apt.16830

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9313579/
https://www.ncbi.nlm.nih.gov/pubmed/35235245
http://dx.doi.org/10.1111/apt.16830

Ejemplares similares